A novel gene on human chromosome 2p24 is differentially expressed between androgen-dependent and androgen-independent prostate cancer cells
European Journal of Cancer , Volume 37 - Issue 16 p. 2129- 2134
Identification of genes involved in the transition from androgen-dependent to androgen-independent prostate cancer is important to extend our current knowledge of the disease. Using differential display RT-PCR analysis between androgen-dependent and androgen-independent prostate cancer cells, we have identified a novel gene, designated GC109. GC109 harbours a putative Cys-His cluster, a nuclear localisation signal, a leucine zipper and a ret finger protein (rfp)-like domain. GC109 mRNA expression in normal human tissues was found not to be restricted to the prostate. However, using a variety of 15 human cancer cell lines, GC109 mRNA was preferentially expressed in androgen-dependent LNCaP-FGC, compared with androgen-independent LNCaP-LNO, DU145 and PC3 human prostate cancer cells. Finally, the GC109 gene was mapped on human chromosome 2p24. Based on its protein domain structure and chromosomal localisation, we hypothesise that GC109 may be involved in chromosomal rearrangements in prostate cancer.
|*Gene Expression Regulation, Neoplastic, Androgens/*physiology, Base Sequence, Blotting, Northern, Chromosome Mapping, Chromosomes, Human, Pair 2/*genetics, Humans, Male, Molecular Sequence Data, Neoplasms, Hormone-Dependent/*genetics/metabolism, Prostatic Neoplasms/*genetics/metabolism, RNA, Messenger/genetics, RNA, Neoplasm/genetics, Reverse Transcriptase Polymerase Chain Reaction, Tumor Cells, Cultured|
|European Journal of Cancer|
|Organisation||Erasmus MC: University Medical Center Rotterdam|
Chang, G.T.G, Steenbeek, M, Schippers, E, Blok, L.J, van Weerden, W.M, van Alewijk, D.C.J.G, … Brinkmann, A.O. (2001). A novel gene on human chromosome 2p24 is differentially expressed between androgen-dependent and androgen-independent prostate cancer cells. European Journal of Cancer, 37(16), 2129–2134. doi:10.1016/S0959-8049(01)00259-3